Adaptimmune Therapeutics annual current ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics Current Ratio Growth & History (ADAPY)
Adaptimmune Therapeutics's current ratio was 2.92 for fiscal 2024.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 2.92 | 0.06 | +2.27% |
| 2023 | 2023-12-31 | 2.85 | −1.11 | −27.98% |
| 2022 | 2022-12-31 | 3.96 | −2.68 | −40.40% |
| 2021 | 2021-12-31 | 6.64 | −3.55 | −34.81% |
| 2020 | 2020-12-31 | 10.19 | 6.68 | +190.43% |
| 2019 | 2019-12-31 | 3.51 | −5.95 | −62.90% |
| 2018 | 2018-12-31 | 9.46 | 6.36 | +205.31% |
| 2017 | 2017-12-31 | 3.10 | −1.84 | −37.24% |
| 2016 | 2016-12-31 | 4.94 | — | — |
| 2015 | 2015-06-30 | 11.02 | — | — |
Adaptimmune Therapeutics quarterly current ratio
Q4.15
Q2.16
Q3.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 1.52 | −1.58 | −50.96% |
| Q1 2025 | 2025-03-31 | 2.02 | −0.80 | −28.34% |
| Q4 2024 | 2024-12-31 | 2.92 | 0.06 | +2.27% |
| Q3 2024 | 2024-09-30 | 3.85 | 0.93 | +31.83% |
| Q2 2024 | 2024-06-30 | 3.09 | −0.35 | −10.08% |
| Q1 2024 | 2024-03-31 | 2.81 | −0.54 | −16.22% |
| Q4 2023 | 2023-12-31 | 2.85 | −1.11 | −27.98% |
| Q3 2023 | 2023-09-30 | 2.92 | −1.08 | −26.97% |
| Q2 2023 | 2023-06-30 | 3.44 | −0.92 | −21.16% |
| Q1 2023 | 2023-03-31 | 3.36 | −2.07 | −38.18% |
| Q4 2022 | 2022-12-31 | 3.96 | −2.68 | −40.40% |
| Q3 2022 | 2022-09-30 | 4.00 | −3.31 | −45.27% |
| Q2 2022 | 2022-06-30 | 4.36 | −3.78 | −46.45% |
| Q1 2022 | 2022-03-31 | 5.43 | −6.04 | −52.65% |
| Q4 2021 | 2021-12-31 | 6.64 | −3.55 | −34.81% |
| Q3 2021 | 2021-09-30 | 7.30 | −4.92 | −40.27% |
| Q2 2021 | 2021-06-30 | 8.15 | −3.73 | −31.44% |
| Q1 2021 | 2021-03-31 | 11.48 | 3.84 | +50.24% |
| Q4 2020 | 2020-12-31 | 10.19 | 6.68 | +190.43% |
| Q3 2020 | 2020-09-30 | 12.23 | 8.30 | +211.17% |
| Q2 2020 | 2020-06-30 | 11.88 | 5.69 | +91.93% |
| Q1 2020 | 2020-03-31 | 7.64 | −0.91 | −10.63% |
| Q4 2019 | 2019-12-31 | 3.51 | −5.95 | −62.90% |
| Q3 2019 | 2019-09-30 | 3.93 | −4.92 | −55.59% |
| Q2 2019 | 2019-06-30 | 6.19 | 2.37 | +62.01% |
| Q1 2019 | 2019-03-31 | 8.55 | 4.78 | +126.81% |
| Q4 2018 | 2018-12-31 | 9.46 | 6.36 | +205.31% |
| Q3 2018 | 2018-09-30 | 8.85 | 5.15 | +138.96% |
| Q2 2018 | 2018-06-30 | 3.82 | −4.04 | −51.38% |
| Q1 2018 | 2018-03-31 | 3.77 | −3.22 | −46.06% |
| Q4 2017 | 2017-12-31 | 3.10 | −1.84 | −37.24% |
| Q3 2017 | 2017-09-30 | 3.70 | −5.10 | −57.95% |
| Q2 2017 | 2017-06-30 | 7.86 | −2.98 | −27.47% |
| Q1 2017 | 2017-03-31 | 6.99 | −5.04 | −41.91% |
| Q4 2016 | 2016-12-31 | 4.94 | −4.50 | −47.67% |
| Q3 2016 · Sep 30 | 2016-09-30 | 8.81 | — | — |
| Q2 2016 · Jun 30 | 2016-06-30 | 10.83 | −0.19 | −1.72% |
| Q3 2016 · Mar 31 | 2016-03-31 | 12.03 | — | — |
| Q2 2016 · Dec 31 | 2015-12-31 | 9.43 | — | — |
| Q4 2015 | 2015-06-30 | 11.02 | — | — |
Adaptimmune Therapeutics current ratio trends
Over the last five fiscal years, Adaptimmune Therapeutics's current ratio decreased from 3.51 to 2.92, a change of −0.59. The latest reported quarter, Q2 2025, shows 1.52.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptimmune Therapeutics source filings ↗